| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NASDAQ |
| Div & Yield | N.A. (N.A) |
Latest News
Chelsea Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate The Acquisition Proposal From H. Lundbeck A/S
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Chelsea...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of Chelsea Therapeutics International, Ltd.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Chelsea Therapeutics International, Ltd.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Of Chelsea Therapeutics International, Ltd. And Its Board Of Directors In Connection With The Sale Of The Company To H. Lundbeck A/S
Levi & Korsinsky is investigating the Board of Directors of Chelsea Therapeutics International, Ltd.
Newman Ferrara LLP Announces Investigation Of Chelsea Therapeutics International Ltd.
Newman Ferrara LLP is investigating potential claims against the board of directors of Chelsea Therapeutics International (“Chelsea”) (Nasdaq: CHTP) concerning the proposed sale of Chelsea to Danish corporation H.
SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Chelsea Therapeutics International, Ltd. In Connection With The Proposed Sale Of The Company To H. Lundbeck A/S
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Chelsea Therapeutics International, Ltd.
Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Chelsea Therapeutics International, Ltd. Stockholders
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Chelsea Therapeutics International, Ltd.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Of Chelsea Therapeutics International, Ltd. And Its Board Of Directors In Connection With The Sale Of The Company To H. Lundbeck A/S
Levi & Korsinsky is investigating the Board of Directors of Chelsea Therapeutics International, Ltd.
Lundbeck to Buy Chelsea Therapeutics for $658M
Central nervous system disorder specialist Chelsea Therapeutics International on Thursday said it had signed up to a bid from Denmark's H. Lundbeck that values its stock at up to $658 million.
Why Chelsea Therapeutics (CHTP) Stock Is Soaring Today
Chelsea Therapeutics (CHTP) soared Thursday amid news that Danish pharmaceutical company H. Lundbeck would takeover the company for up to $658 million.
Chelsea Exits in Victory With Lundbeck Takeout
Chelsea CEO Joe Oliveto and his team deserve a lot of credit for cleaning up some messy Northera clinical trials, scoring at the FDA advisory panel, securing the drug's approval and now delivering on the exit strategy that everyone wanted.
Chelsea Therapeutics International Enters Oversold Territory (CHTP)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
First Week of CHTP May 17th Options Trading
Investors in Chelsea Therapeutics International Ltd saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CHTP options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
Chelsea Therapeutics International Ltd. (CHTP) Shares Soar 14%
Wedbush believed that Chelsea Therapeutics International is an attractive acquisition or partnership target for multiple pharmaceutical companies because of the approval of NortheraThe stock price of ...
'Mad Money' Lightning Round: Zynga Can Go Higher
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
Cramer will be watching a number of conferences for a read on the economy.